You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Downloads and resources

Document icon

JazzCares enrollment form

The JazzCares program at Jazz Pharmaceuticals provides reimbursement and coverage information for your patients receiving VYXEOS

Brochure icon

VYXEOS patient brochure

Provide your patients with information about their treatment with VYXEOS

Clipboard with checkmark

VYXEOS preparation instructions

A quick reference of VYXEOS preparation instructions

Information about acute myeloid leukemia (AML)

The Leukemia & Lymphoma Society

www.lls.org

1-800-955-4572

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.